Dogwood Q2 Loss Widens on $6.7M Impairment; Halneuron Phase 2b Topline Data on Track for Fall

summarizeSummary

Dogwood Therapeutics reported a Q2 net loss of $11.5 million, including a $6.7 million non-cash impairment, while confirming its Halneuron Phase 2b trial is on track for top-line results this fall.

check_boxKey Events · Earnings and Guidance · DWTX

• Q2 Net Loss Widens on Impairment

  Net loss attributable to common stockholders was $11.5 million, or $0.34 per share, compared to $3.8 million, or $1.99 per share, in Q2 2025. The increase was driven by a $9.2 million non-cash IPR&D impairment charge, partially offset by a $2.5 million deferred tax benefit.

• Cash Runway Through Phase 2b Readout

  Cash on hand of $9.6 million as of June 30, 2026, provides operational runway through the Halneuron Phase 2b top-line results expected in Q4 2026.

• Halneuron Phase 2b Enrollment Progress

  217 patients enrolled in the Phase 2b CINP trial, with top-line results expected in fall 2026. The company anticipates enrolling over 220 patients to achieve 80+% statistical power.

• SP16 IND Approval and NCI Funding

  SP16 received FDA IND approval for chemotherapy-induced pain and peripheral neuropathy (CIPPN). The Phase 1b study is fully funded by the National Cancer Institute and will begin enrolling in H2 2026.

auto_awesomeAnalysis · DWTX · Life Sciences

A $6.7 million non-cash IPR&D impairment charge drove Dogwood's Q2 net loss to $11.5 million. The company's $9.6 million cash position provides runway through the Phase 2b readout in Q4 2026. The filing also disclosed several positive developments: 217 patients enrolled in the Halneuron Phase 2b CINP trial with top-line results expected this fall, FDA IND approval for SP16, and a new partnership for legacy antiviral assets with potential value up to $100 million. The impairment charge is non-cash and does not affect the cash runway, but it reflects a decline in the company's stock price and market capitalization below stockholders' equity.